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First described by Rogers, thiamine-responsive
megaloblastic anaemia (TRMA) is a rare autosomal-
recessive disorder characterised by megaloblastic
anaemia, insulin-dependent diabetes mellitus and
sensorineural deafness.1
The diagnosis is supported by a megaloblastic bone
marrow, particularly the presence of ringed sideroblasts.
Paranuclear iron-laden mitochondria are seen in
normoblasts on electron microscopy.2 The diagnosis can
be confirmed by demonstrating apoptosis in fibroblasts
cultured in thiamine-free medium.3 DNA sequencing has
demonstrated mutations in the TRMA gene; a thiamine
transporter gene SLC19A2.4
The condition responds variably to thiamine. Anaemia
resolves but a degree of macrocytosis persists. Insulin
requirements usually decrease but the deafness is
irreversible. 
We present a 2-year-old girl with the condition, and
review the literature of this disorder.
Case report
A 2-year-old girl was seen at a regional hospital at the age
of 1 year with severe macrocytic anaemia and diabetic
ketoacidosis (DKA). She was transfused and commenced
on folate and was discharged off insulin without further
monitoring of her blood glucose. At follow-up she was
found to have a chronic macrocytic anaemia with a high
serum lactate dehydrogenase.  A presumptive diagnosis
of a congenital haemolytic disorder was made, and she
was maintained on folate. 
After another episode of DKA, she was referred to our
service.  There was no history of neonatal jaundice, and
no family history of anaemia or consanguinity. Her motor
milestones were normal but she had never acquired
meaningful speech, being able only to babble. 
She was well nourished, pale without jaundice and there
were no dysmorphic features. She was profoundly deaf.
Audiological assessment confirmed severe bilateral
sensorineural hearing loss. Control of her diabetes
required 18 units of insulin daily.
Her haemoglobin concentration was 5.4 g/dl with a mean
cell volume of 101 fl, and a reticulocyte count of 68 x 109/l
(1.4% corrected). The white cell count and differential
count were normal, as was the platelet count. The smear
revealed oval macrocytes and poikilocytosis. Red cell
folate (2 114 ng/ml), serum vitamin B12 (615 pg/ml) and
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Megaloblastic anaemia in childhood usually occurs as a result of dietary folate deficiency or, rarely, congenital disorders
of vitamin B12 metabolism. 
We present a 2-year-old girl with megaloblastic anaemia and insulin-dependent diabetes mellitus, both of which proved
responsive to pharmacological doses of thiamine. She was also found to have sensorineural hearing loss.
Also known as Rogers’ syndrome, thiamine-responsive megaloblastic anaemia is the result of inactivating mutations in
a gene encoding a thiamine transporter.
A clinical diagnosis is supported by characteristic bone marrow findings and can be confirmed by demonstrating
apoptosis in skin fibroblasts cultured in thiamine-depleted medium. Where available, DNA sequencing is definitive.
There is rapid reticulocytosis after thiamine administration. We recommend a trial of therapy for megaloblastic anaemia
not responding to folate and vitamin B12, especially in a deaf and/or diabetic child.









































haemolysis were negative. The glycosylated haemoglobin
level was 5.7% (normal 2.9 - 4.6%), indicating satisfactory
glycaemic control. Bone marrow examination revealed a
hypercellular marrow with marked erythroid hyperplasia
and trilineage dysplasia. Erythropoiesis was markedly
megaloblastic but the granulocyte series had only
occasional giant bands. Megakaryocytes had both
exploded and bare nuclei. A Perl’s Prussian blue stain
showed numerous ringed sideroblasts (20%). Owing to
technical difficulties, electron microscopy failed to
demonstrate iron deposits in the mitochondria.
Suspecting the diagnosis of TRMA, we administered an
intramuscular loading dose of 100 mg of thiamine,
followed by 50 mg daily by mouth. There was a rapid
reticulocytosis – the corrected reticulocyte count rose
from 1.4% to 10.2% within a week, and the haemoglobin
concentration increased from a post-transfusion value of
7.7 g/dl to 9.8 g/dl after 14 days. Her daily insulin
requirements fell to 4 units.
Fibroblasts were later obtained from a skin biopsy, and
cultured in Dulbecco’s minimal essential medium
supplemented with 10% fetal calf serum. Substitution
with commercially obtained medium specifically
formulated to be thiamine-free failed to induce the
characteristic apoptosis. This was possibly because of
trace amounts of thiamine present in the fetal calf serum
used. DNA sequencing was not available.
The patient was given a hearing aid, and discharged to
the regional hospital on lifelong thiamine
supplementation.
Three years after diagnosis the patient maintains a
haemoglobin concentration of 12.2 g/dl with a mean cell
volume of 92 fl, and  requires 3 - 5 units of insulin daily.
She has been referred to a school for deaf children.
Discussion
Rogers et al .5 first reported TRMA in 1969. They described
an 11-year-old girl with megaloblastic anaemia, diabetes
and deafness. The molecular biology has recently been
elucidated. 
This autosomal-recessive disorder is the result of
mutations of the SLC19A2 gene located on chromosome 1.
First identified in 1999,6 the product of this gene is a high-
affinity thiamine transporter3 that mediates facilitated
transport of thiamine across cell membranes. The rapid
transport of thiamine by this facilitated transport system
appears to be essential only for haematopoietic,
pancreatic islet and auditory nerve cell function. Passive
uptake by a separate low-affinity, high-capacity system
appears adequate to protect other tissues from
intracellular thiamine depletion. Hence TRMA patients
with adequate dietary thiamine seldom manifest the
classic signs of severe thiamine deficiency typical of
beriberi, including peripheral neuropathy, cardiomyopathy
and central nervous system involvement.
A consequence of intracellular thiamine depletion is a
decrease in activity of thiamine-dependent transketolase,
thereby critically reducing the synthesis of ribose via the
non-oxidative arm of the pentose phosphate pathway.7
Lack of ribose for nucleic acid synthesis leads to cell-cycle
arrest and triggers apoptosis. It has been suggested that
cumulative cell loss in sensitive tissues explains why the
clinical manifestations are not apparent in early infancy.8
The gradual decline in glucose tolerance seen in our
patient is consistent with this hypothesis.
Thiamine supplementation in pharmacological doses can
compensate to a degree by increasing passive uptake via
the low-affinity system. The ability of pluripotent
haematopoietic stem cells to repopulate the bone marrow
after the death of thiamine-deficient red cell precursors
explains the recovery of the red cell indices. Ongoing
macrocytosis demonstrates that their thiamine-replete
successors remain sensitive to the high-affinity transport
defect.3 Low-turnover pancreatic beta cells and auditory
nerve cells presumably require thiamine primarily to
maintain their adenosine triphosphate (ATP) levels by
oxidative phosphorylation, rather than for nucleic acid
synthesis. Beta cells seem to be of intermediate sensitivity
to intracellular thiamine depletion, demonstrating a
degree of recovery with supplementation, whereas
auditory nerve cells are exquisitely sensitive, presumably
because of their higher energy requirements. Here
ongoing apoptosis results in irreversible deafness.
Our patient ran a typical course with rapid improvement
in the anaemia and a partial response with regard to
insulin requirements. The sensorineural hearing loss has
not improved, and this is consistent with the experience
of others.1
We suggest that the typical clinical presentation together
with megaloblastosis in the face of normal vitamin B12 and
folate levels should prompt a therapeutic trial of thiamine.
Fibroblast culture or DNA sequencing would be definitive.
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